Shares of Eton Pharmaceuticals ETON fell 1.5% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 27.78% year over year to ($0.23), which beat the estimate of ($0.26).
Revenue of $20,000 up by 0.00% year over year, which missed the estimate of $290,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Aug 12, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/5n7zmi26
Technicals
52-week high: $8.74
Company's 52-week low was at $2.50
Price action over last quarter: Up 37.05%
Company Overview
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eight product candidates in various stages of development.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
